The pharmaceutical contract research and manufacturing market share is forecast to reach USD 121.35 billion, after growing at a CAGR of 10.32% during 2022-2027. The availability of cost-efficient resources in emerging markets is analyzed to boost pharmaceutical contract research and manufacturing market growth. Moreover, growing concern over the patent expiries of various small as well as large molecules is the major trend enhancing the overall market demand for pharmaceutical contract research and manufacturing during the forecast period.
Get a snapshot on the pharmaceutical contract research and manufacturing market analysis: Unlock the Sample Report
Browse Technavio's 167-page report and in-depth TOC on "Pharmaceutical Contract Research and Manufacturing Market by service (CMO and CRO), end-user (big pharmaceuticals, small and medium-sized pharmaceuticals, and generic pharmaceuticals), and geography (North America, Asia, Europe, and Rest Of World (ROW)).
View detailed Table of Contents Here: https://www.technavio.com/report/pharmaceutical-contract-research-and-manufacturing-market-industry-analysis
CMO: The market share growth of the CMO segment will be significant during the forecast period. Developments such as nanotechnology and stem cell research, are leading to the emergence of drugs, creating demand for more composite manufacturing processes
North America: Asia is estimated to contribute 41% to the growth of the global market during the forecast period. Another region offering significant growth opportunities to vendors is North America.
Rest of World (ROW)
Small and medium-sized pharmaceuticals
The pharmaceutical contract research and manufacturing market size will witness a YOY Growth Rate of 9.35% in 2023.
The stereotypical nature of CMOs will be a major challenge for the pharmaceutical contract research and manufacturing market during the forecast period.
Major key pharmaceutical contract research and manufacturing market players include: Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd., Dr Reddys Laboratories Ltd., ICON plc, IQVIA Holdings Inc., Laboratory Corp. of America Holdings, Lonza Group Ltd., Lupin Ltd., Recipharm AB, Samsung Electronics Co. Ltd., Syneos Health Inc., Thermo Fisher Scientific Inc., PCI Pharma Services, Parexel International Corp., OPTIMAPHARM d.o.o., and Novotech Australia Pty Ltd.
The report illustrates the lifecycle of the market, focusing on the adoption rates of the major regions such as North America, Asia, Europe, and the Rest of the World (ROW).
Download the PDF sample report for highlights on the market size, growth momentum, regional growth opportunities, vendor analysis, and other factors influencing the market growth.
Precise market size estimation during the forecast period 2023-2027.
CAGR of the pharmaceutical contract research and manufacturing market forecast during 2023-2027.
Market-level data on units, average selling prices, and values of the pharmaceutical contract research and manufacturing market share.
Prediction of the upcoming trends, drivers, and factors that challenge the growth of the pharmaceutical contract research and manufacturing market.
Pharmaceutical contract research and manufacturing industry growth across North America, Asia, Europe, and Rest Of World (ROW).